Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24345245 | 0.92 | — | — | |
| SCHEMBL1077286 | 0.77 | TSHR (0.33) | TSHRMAPK1SMN1; SMN2CYP11B1CYP11B2 | |
| SCHEMBL24345246 | 0.75 | — | — | |
| SCHEMBL18236377 | 0.73 | — | — | |
| Iodide SCHEMBL17911357 | 0.65 | MEN1 (0.33) | MEN1KMT2A | |
| SCHEMBL15353266 | 0.65 | CDK4 (0.38) | MEN1KMT2ATSHRMAPK1SMN1; SMN2 | |
| SCHEMBL16406998 | 0.64 | ALOX15 (0.35) | — | |
| SCHEMBL18844450 | 0.63 | CA2 (0.38) | KMT2ANPSR1 | |
| Bromide SCHEMBL9328086 | 0.63 | KMT2A (0.35) | MEN1KMT2ANPSR1 | |
| SCHEMBL31142144 | 0.63 | HSD11B1 (0.33) | MEN1KMT2ANPSR1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11691135-B2 | Synthesis of alkynones via carbonylative Sonogashira coupling reactions catalyzed by Pd(II)-N-Heterocyclic carbene-pyridine complexes | KING FAHD UNIVERSITY OF PETROLEUM & MINERALS (SA) | 2023-07-04 | — | — | US | disclosed |
| WO-2022081953-A1 | SYNTHESIS OF ALKYNONES VIA CARBONYLATIVE SONOGASHIRA COUPLING REACTIONS CATALYZED BY PD(II)-N-HETEROCYCLIC CARBENE-PYRIDINE COMPLEXES | SAUDI ARABIAN OIL COMPANY (SA) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11691135-B2 | Synthesis of alkynones via carbonylative Sonogashira coupling reactions catalyzed by Pd(II)-N-Heterocyclic carbene-pyridine complexes | PDK2, SNCA, YAP1 | MEN1 1330/4885KMT2A 1519/4885NPSR1 1756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.